Current use of glucocorticoids in patients with rheumatoid arthritis in Germany
Open Access
- 5 October 2005
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 53 (5), 740-747
- https://doi.org/10.1002/art.21467
Abstract
Objective To describe the current use of glucocorticoids in German patients with rheumatoid arthritis (RA). Methods We analyzed clinical and patient‐derived data from 10,068 outpatients with RA from the national database of the German Collaborative Arthritis Centres for the year 2001 collected by more than 80 rheumatologists in hospitals and private practices. Results Systemic glucocorticoid therapy was prescribed for 60% of all patients with RA in rheumatologic care. The proportion of patients receiving systemic glucocorticoids in addition to disease‐modifying antirheumatic drug (DMARD) therapy ranged from 53% to 81% of the patients for the various DMARDs. Glucocorticoid therapy was administered more often in combination with tumor necrosis factor inhibitors (81%), cyclosporin A (80%), or leflunomide (77%) than with more traditional DMARDs such as methotrexate (63%) or sulfasalazine (55%). Regarding the prevention and treatment of osteoporosis, 63% of patients taking systemic glucocorticoids were also receiving some type of osteoporosis therapy, as opposed to only 26% of those not taking glucocorticoids. Conclusion Glucocorticoids play a pivotal role in the management of RA. This is reflected in the extensive use of low‐dose glucocorticoids by German rheumatologists. Even if highly effective DMARDs are prescribed, they are accompanied by glucocorticoids, at least in the initial phase. High‐dose glucocorticoids are prescribed for only a small proportion of the patients. There is increasing awareness of the risk of osteoporosis in long‐term glucocorticoid treatment, demonstrated by the fact that osteoporosis medication is prescribed for a large proportion of patients taking glucocorticoids.This publication has 35 references indexed in Scilit:
- Anakinra, a recombinant human interleukin‐1 receptor antagonist (r‐metHuIL‐1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo‐controlled trialArthritis & Rheumatism, 2003
- Missed opportunities in physician management of glucocorticoid‐induced osteoporosis?Arthritis & Rheumatism, 2002
- Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatologyAnnals Of The Rheumatic Diseases, 2002
- COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief interventionArthritis & Rheumatism, 2002
- Etanercept Therapy in Rheumatoid ArthritisAnnals of Internal Medicine, 1999
- Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritisThe Lancet, 1997
- Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional studyBMJ, 1996
- The Effect of Glucocorticoids on Joint Destruction in Rheumatoid ArthritisThe New England Journal of Medicine, 1995
- Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse eventsThe American Journal of Medicine, 1994
- Corticosteroid Use and Peptic Ulcer Disease: Role of Nonsteroidal Anti-inflammatory DrugsAnnals of Internal Medicine, 1991